Clinical Research
Filter News
Found 138,696 articles
-
This week, researchers published results from studies on treatments in lung disease, Alzheimer’s and various cancers. Here's a look at that and more.
-
Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint
9/30/2022
Intercept Pharmaceuticals, Inc. today announced that REVERSE, a Phase 3 study evaluating the safety and efficacy of OCA in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH).
-
Accuray Announces First CyberKnife® Systems in Africa, Providing a New Option and Hope for Potentially Life-Saving Radiation Treatments for More Cancer Patients
9/30/2022
Accuray Incorporated (NASDAQ: ARAY) announced today the company is expanding its global footprint with the introduction of its CyberKnife ® platform in Africa.
-
Mersana Therapeutics Announces Launch of Oncology FACETS, a Resource for Healthcare Providers to Advance Knowledge in Gynecologic Malignancies
9/30/2022
Mersana Therapeutics, Inc. today announced the launch of Oncology FACETS : an educational platform for healthcare providers that will address clinically impactful topics in gynecologic oncology.
-
Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform
9/30/2022
Todos Medical, Ltd. today announced that it has received two Notices of Allowance from the United States Patent & Trademark Office (USPTO) for patent applications covering the Company’s Total Biochemical Infrared Analysis (TBIA) Fourier Transformed Infrared (FTIR) pan-cancer blood diagnostics platform.
-
Biolog-id completed phase one of deploying its value-chain optimization solution in a multi-state integrated delivery network in the southeast USA
9/30/2022
Biolog-id has completed phase one of implementing its value-chain optimization solution in a large medical center and level II trauma center in North Carolina.
-
Seelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program
9/30/2022
Seelos Therapeutics, Inc. today announced it will collaborate with the Sean M. Healey & AMG Center for ALS in an Expanded Access Program (EAP) that will be fully funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS.
-
EnPlusOne Biosciences Launches Enzymatic RNA Synthesis Platform with $12 Million in Seed Financing
9/30/2022
EnPlusOne Biosciences Launches Enzymatic RNA Synthesis Platform with $12 Million in Seed Financing.
-
Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study
9/30/2022
Edesa Biotech, Inc. announced final results from the Phase 2 portion of its ongoing Phase 2/Phase 3 clinical study.
-
Forza Innovations Announces Completion of New Funding Round
9/30/2022
Forza Innovations Inc. today announced the completion of a new tranche of funding, totaling $250,000.
-
Trinity Biotech Announces Results of AGM
9/30/2022
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the results of an Annual General Meeting (AGM).
-
CXL Ophthalmics Announces $32 Million Series A Investment Round Led by AXA IM Alts
9/30/2022
CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today announced it has raised a $32 million Series A funding round led by AXA IM Alts through its Global Health Private Equity.
-
Applied DNA’s Biotherapeutics Subsidiary Publishes Manuscript Demonstrating that a LinearDNA™ Vaccine Candidate was Protective in Virus Challenge Trial in Ferrets
9/30/2022
Applied DNA Sciences, Inc. today announced the publication of a manuscript, co-authored with international academic and industry scientists, containing data demonstrating that a LinearDNA™-based vaccine candidate (the “vaccine candidate”) reduced infectious virus shedding and was protective against SARS-CoV-2 in a challenge trial in ferrets.
-
e-therapeutics: Fundraise of £13.5 million
9/30/2022
e-therapeutics plc is pleased to announce a fundraise of £13.5 million before expenses by way of a subscription for new ordinary shares of 0.1p each ("Ordinary Shares") in the Company (the "Subscription") at a price of 20p per Ordinary Share by funds managed by M&G Investment Management Limited ("M&G"), an institutional investor and an existing shareholder of the Company.
-
Zoetis Announces the Completion of its Acquisition of Jurox, a Leading Provider of Livestock and Companion Animal Products
9/30/2022
Zoetis Inc today announced it has completed the acquisition of Jurox, a privately held animal health company that develops, manufactures and markets a wide range of veterinary medicines for treating livestock and companion animals.
-
IMV Provides an Update on The VITALIZE Trial
9/30/2022
IMV Inc. today provided an update on the open-label VITALIZE study evaluating its lead product maveropepimut-S (MVP-S) in combination with pembrolizumab and intermittent low-dose cyclophosphamide (CPA) in patients with relapses, refractory diffuse large B cell lymphoma (r/r DLBCL).
-
Ainos Announces Positive Results from Additional Preclinical Study of Its Low-dose Oral Interferon Formulation Against New Variant Virus - Omicron
9/30/2022
Ainos today announced the results from its antiviral efficacy study in hamsters against the Omicron variant of SARS-CoV-2 (the "Study").
-
Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)
9/30/2022
Zealand Pharma A/S announced positive topline results from the pivotal Phase 3 trial of glepaglutide, a long-acting GLP-2 analogue designed for once or twice weekly subcutaneous delivery via auto-injector, in patients with short bowel syndrome.
-
Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified Interim Analysis of Efficacy and Safety
9/30/2022
Kinarus Therapeutics Holding AG announced that the independent Data and Safety Monitoring Board has completed its prespecified data review for the Phase 2 KINETIC study in hospitalized COVID-19 patients, and has recommended discontinuation of the study.
-
Ordaōs and NonExomics announced a research pact Wednesday to develop mini-proteins, called miniPROs, for three specific difficult-to-target rare cancers.